A Phase 4 interventional study of dorzolamide/timolol in Glaucoma, Open-Angle and Glaucoma; Drugs, sponsored by CT Glaucoma Associates. Terminated at 1 site in United States. Open to participants aged 25 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-23.
Sponsored by CT Glaucoma Associates · Phase 4, Interventional, and Treatment
IOP effect of half-dose latanoprost dorzolamide-timolol will be compared to full dose. Further comparison will be made timolol-brimonidine-dorzolamide-bimatoprost. Dry eye effects of the different treatments will be assessed.
Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later.
At each study visit, dry eye signs will be assessed and brief dry eye survey will be administered.
943 studies on the registry are indexed under Glaucoma, Open-Angle; 118 are open to participants now.
This study's enrollment of 36 is below the median of 80 across 710 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →This is the only study on the registry with CT Glaucoma Associates as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The final determination to be included in the study will be made by the Physician on the day of the appointment.
After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.
Drug: dorzolamide/timolol
After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.
Drug: dorzolamide/timolol
Drug pages: Dorzolamide · Timolol
Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
Also known as: latanoprost, timolol/brimonidine/dorzolamide/bimatoprost
intraocular pressure
measured by pneumatonometry and Goldmann tonometry
Time frame: 3 weeks after each phase
dry eye
assess punctate staining of cornea and subjective symptoms
Time frame: 3 weeks after each phase
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Jul 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dorzolamide · Timolol